MA29872B1 - Procede d'amelioration de la fonction cognitive - Google Patents

Procede d'amelioration de la fonction cognitive

Info

Publication number
MA29872B1
MA29872B1 MA30850A MA30850A MA29872B1 MA 29872 B1 MA29872 B1 MA 29872B1 MA 30850 A MA30850 A MA 30850A MA 30850 A MA30850 A MA 30850A MA 29872 B1 MA29872 B1 MA 29872B1
Authority
MA
Morocco
Prior art keywords
subject
cognitive function
improving
homozygous
apoe4
Prior art date
Application number
MA30850A
Other languages
English (en)
Inventor
Allen D Roses
Ann M Saunders
Original Assignee
Sb Pharmco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37876831&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA29872(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sb Pharmco Inc filed Critical Sb Pharmco Inc
Publication of MA29872B1 publication Critical patent/MA29872B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Méthode d'amélioration de la fonction cognitive Une méthode pour améliorer la fonction cognitive chez un sujet souffrant de, ou sensible à, la MCI, la maladie d'Alzheimer ou d'autres démences, sujet qui n'est pas homozygote pour l'allèle APOE4, comprenant les étapes consistant : i) à soumettre le sujet à un dépistage pour déterminer que le sujet n'est pas homozygote pour l'allèle APOE4 ; et ensuite ii) à administrer une quantité sûre et efficace d'un agoniste de PPAR-gamma audit sujet.
MA30850A 2005-09-22 2008-04-15 Procede d'amelioration de la fonction cognitive MA29872B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71935305P 2005-09-22 2005-09-22
US72737705P 2005-10-17 2005-10-17

Publications (1)

Publication Number Publication Date
MA29872B1 true MA29872B1 (fr) 2008-10-03

Family

ID=37876831

Family Applications (2)

Application Number Title Priority Date Filing Date
MA30850A MA29872B1 (fr) 2005-09-22 2008-04-15 Procede d'amelioration de la fonction cognitive
MA30849A MA29871B1 (fr) 2005-09-22 2008-04-15 Composition pharmaceutique concue pour ameliorer la fonction cognitive

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA30849A MA29871B1 (fr) 2005-09-22 2008-04-15 Composition pharmaceutique concue pour ameliorer la fonction cognitive

Country Status (16)

Country Link
US (2) US20080262047A1 (fr)
EP (2) EP1926488A2 (fr)
JP (2) JP2009508960A (fr)
KR (2) KR20080056731A (fr)
AR (2) AR055649A1 (fr)
AU (2) AU2006295010A1 (fr)
BR (2) BRPI0616100A2 (fr)
CA (2) CA2623210A1 (fr)
CR (2) CR9848A (fr)
EA (2) EA200800879A1 (fr)
IL (2) IL190217A0 (fr)
MA (2) MA29872B1 (fr)
NO (2) NO20081847L (fr)
PE (2) PE20070976A1 (fr)
TW (2) TW200803851A (fr)
WO (2) WO2007038115A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2663347A1 (fr) * 2006-09-19 2008-03-27 Braincells, Inc. Modulation induite par ppar de la neurogenese
IL187159A0 (en) * 2007-07-03 2009-02-11 Gur Megiddo Use of metadoxine in relief of alcohol intoxication
WO2009043593A1 (fr) * 2007-10-05 2009-04-09 Merz Pharma Gmbh & Co. Kgaa Thérapie de combinaison utilisant la mémantine et les glitazones
EP2085120A1 (fr) * 2008-02-01 2009-08-05 Merz Pharma GmbH & Co. KGaA Utilisation de substances pour le traitement d'une déficience de récepteur d'insuline périphérique ou central et résistance à l'insuline
CN102177436B (zh) 2008-08-12 2015-05-13 金帆德尔制药股份有限公司 鉴定疾病风险因子的方法
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
US20100152249A1 (en) * 2008-12-11 2010-06-17 Board Of Trustees Of The Leland Stanford Junior University Compositons and method for treatment of mood and cognitive impairments
NZ597319A (en) * 2009-06-25 2014-06-27 Alcobra Ltd A method for the treatment, alleviation of symptoms of, relieving, improving and preventing a cognitive disease, disorder or condition
US20100178307A1 (en) * 2010-01-13 2010-07-15 Jianye Wen Transdermal anti-dementia active agent formulations and methods for using the same
WO2012053016A1 (fr) * 2010-10-22 2012-04-26 Cadila Healthcare Limited Compositions pharmaceutiques de donépézil à libération prolongée
MX358594B (es) * 2011-01-10 2018-08-27 Zinfandel Pharmaceuticals Inc Factores de riesgo de enfermedad y métodos de uso.
MX355479B (es) 2011-01-10 2018-04-19 Zinfandel Pharmaceuticals Inc Metodos y productos de farmaco para tratar enfermedad de alzheimer.
US9907789B2 (en) 2011-10-21 2018-03-06 Takeda Pharmaceutical Company Limited Sustained-release preparation
WO2013063086A1 (fr) * 2011-10-24 2013-05-02 Intellect Neurosciences, Inc. Compositions et méthodes de traitement de protéinopathies
EP2987489A4 (fr) * 2013-04-19 2016-09-07 Takeda Pharmaceutical Formulation de médicament à libération contrôlée
WO2018022604A2 (fr) * 2016-07-26 2018-02-01 Ausio Pharmaceuticals, Llc Méthodes de diagnostic et de traitement de la maladie d'alzheimer par s-équol
US20180153859A1 (en) * 2016-12-02 2018-06-07 T3D Therapeutics, Inc. Methods of treating or preventing cognitive impairment using indane acetic acid derivatives based on apoe4 genotype
KR102224918B1 (ko) 2018-03-20 2021-03-09 (주)인벤티지랩 도네페질 및 메만틴을 포함하는 인지 장애 관련 질병의 예방 또는 치료용 약학적 복합 조성물 및 이의 제조 방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2142300C (fr) * 1992-10-13 2005-08-23 Allen D. Roses Methode de depistage de la maladie d'alzheimer
US6191154B1 (en) * 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
DE69942672D1 (de) * 1998-12-17 2010-09-23 Mindset Biopharmaceuticals Usa Verbesserung der geistigen fähigkeiten durch die steigerung der insulin-empfindlichkeit des gehirns
EP1718294A4 (fr) * 2004-01-30 2007-10-03 Axonyx Inc Methodes de traitement de complications du diabete

Also Published As

Publication number Publication date
AR056527A1 (es) 2007-10-10
BRPI0616192A2 (pt) 2011-06-14
NO20081843L (no) 2008-06-16
TW200803851A (en) 2008-01-16
AR055649A1 (es) 2007-08-29
KR20080056731A (ko) 2008-06-23
KR20080058413A (ko) 2008-06-25
WO2007038112A2 (fr) 2007-04-05
JP2009508960A (ja) 2009-03-05
IL190224A0 (en) 2008-11-03
EA200800880A1 (ru) 2009-02-27
CR9848A (es) 2008-06-18
JP2009508959A (ja) 2009-03-05
AU2006295010A1 (en) 2007-04-05
EP1940403A2 (fr) 2008-07-09
US20080226719A1 (en) 2008-09-18
NO20081847L (no) 2008-06-18
BRPI0616100A2 (pt) 2011-06-07
PE20070618A1 (es) 2007-07-04
PE20070976A1 (es) 2007-12-05
CA2623204A1 (fr) 2007-04-05
EP1926488A2 (fr) 2008-06-04
TW200803896A (en) 2008-01-16
WO2007038112A3 (fr) 2007-12-06
CA2623210A1 (fr) 2007-04-05
US20080262047A1 (en) 2008-10-23
WO2007038115A2 (fr) 2007-04-05
WO2007038115A3 (fr) 2007-12-13
AU2006295007A1 (en) 2007-04-05
EA200800879A1 (ru) 2008-10-30
CR9849A (es) 2008-05-21
IL190217A0 (en) 2008-11-03
MA29871B1 (fr) 2008-10-03

Similar Documents

Publication Publication Date Title
MA29872B1 (fr) Procede d'amelioration de la fonction cognitive
Higuchi et al. Mutations in MME cause an autosomal‐recessive Charcot–Marie–Tooth disease type 2
Levy et al. Phenotypic and genotypic characteristics of cryopyrin-associated periodic syndrome: a series of 136 patients from the Eurofever Registry
Plecko et al. Confirmation of mutations in PROSC as a novel cause of vitamin B 6-dependent epilepsy
Coutelier et al. GRID2 mutations span from congenital to mild adult-onset cerebellar ataxia
Nazarov et al. The angiotensin converting enzyme I/D polymorphism in Russian athletes
Yamin et al. ACE ID genotype affects blood creatine kinase response to eccentric exercise
Bacon et al. Very Early Changes in Olfactory Functioning Due to Alzheimer's Disease and the Role of Apolipoprotein E in Olfaction a
Ratia et al. Huprine X and huperzine A improve cognition and regulate some neurochemical processes related with Alzheimer’s disease in triple transgenic mice (3xTg-AD)
AR043188A1 (es) Metodos y composiciones para el tratamiento de enfermedades y trastornos asociados con niveles elevados de citoquinas proinflamatorias
Himori et al. Superoxide dismutase/catalase mimetic EUK-134 prevents diaphragm muscle weakness in monocrotalin-induced pulmonary hypertension
Patterson et al. DMRT 3 is associated with gait type in Mangalarga Marchador horses, but does not control gait ability
Negishi et al. Involvement of complement 3 in the salt-sensitive hypertension by activation of renal renin-angiotensin system in spontaneously hypertensive rats
Pasha et al. Variations in angiotensin-converting enzyme gene insertion/deletion polymorphism in Indian populations of different ethnic origins
Sargent Synthesis of acetylcholine by excitatory motoneurons in central nervous system of the leech
Loos et al. Independent genetic loci for sensorimotor gating and attentional performance in BXD recombinant inbred strains
Min et al. Is there a gender difference between ACE gene and race distance?
WO2001020031A3 (fr) Polymorphismes dans un gene klotho
WO2004107958A3 (fr) Marqueurs de sterol utilises en tant qu'outils de diagnostic dans la prevention des maladies atherosclereuses et en tant qu'outils d'aide a la selection d'agents a utiliser dans la prevention et le traitement de maladies atherosclereuses
Altamura et al. What is the relationship among atherosclerosis markers, apolipoprotein E polymorphism and dementia?
Lagerwaard et al. Matrisome, innervation and oxidative metabolism affected in older compared with younger males with similar physical activity
Takeda et al. Intrastriatal grafts of fetal ventral mesencephalon improve allodynia-like withdrawal response to mechanical stimulation in a rat model of Parkinson's disease
NO20061383L (no) Substituerte aryl cykloalkanolderivater og fremgangsmater for anvendelse derav
Bailey et al. Identification of quantitative trait loci for locomotor activation and anxiety using closely related inbred strains
Manganelli et al. A novel autosomal dominant GDAP1 mutation in an Italian CMT2 family